ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Associations of symptom burden with patient-reported outcomes and clinical outcomes among early phase cancer clinical trial participants.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIndividuals with cancer often endure a substantial symptom burden. However, little is known about the symptom burden of patients with cancer participating in early phase cancer clinical trials (EPCT).
methodsWe prospectively enrolled adults with cancer participating in EPCTs at Massachusetts General Hospital from 4/2021-1/2023. Participants completed surveys prior to EPCT initiation that assessed symptoms (Edmonton Symptom Assessment System [ESAS]), quality of life (QOL; Functional Assessment of Cancer Therapy-General), depression/anxiety symptoms (Patient Health Questionnaire-4), and financial well-being (COST). We used regression models to explore associations of symptom burden with patient-reported outcomes and clinical outcomes.
resultsAmong 195 patients enrolled, 185 participants completed the surveys (94.9% response rate). Participants had a median age of 63.5 years (range: 31.8-88.6) and 57.3% were female. Most common cancer types were gastrointestinal and breast. Median survival was 7.82 (IQR: 3.88-18.71) months, and median follow-up time was 12.20 (IQR: 7.99-16.80) months. Participants reported moderate/severe fatigue (51.7%), poor well-being (49.7%), drowsiness (36.2%), pain (26.4%), and lack of appetite (25.8%). Higher ESAS-total scores and greater number of moderate/severe symptoms were associated with lower QOL, increased depression/anxiety symptoms, and worse financial well-being (p-values < 0.05 for all). Higher ESAS-total scores (HR:1.02, p < 0.001) were associated with worse overall survival.
conclusionAmong EPCT participants, higher symptom burden at time of clinical trial initiation correlated with decreased QOL, increased depression/anxiety symptoms, worse financial well-being, shorter time on trial, and worse overall survival. Interventions seeking to enhance care delivery and outcomes for EPCT participants should strive to address the symptom burden of this population.
Indexed as
Identifiers
42274780What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.